As drug and device consultants, the scientists and regulatory experts at PDG® spend a considerable amount of time working on 505(b)(2) NDA submissions. This paper highlights notable features of a cross section of recent 505(b)(2) approvals and provides a variety of everyday issues to consider as you contemplate your next drug development project.
Recent comments
10 years 42 weeks ago
12 years 20 weeks ago
12 years 20 weeks ago
12 years 20 weeks ago
12 years 20 weeks ago
12 years 20 weeks ago
12 years 20 weeks ago
12 years 24 weeks ago
12 years 24 weeks ago
12 years 24 weeks ago